BACKGROUND: There is no proven treatment for stroke progression in patients with subcortical infarcts. Eptifibatide, a glycoprotein IIb/IIIa inhibitor, might halt stroke progression by improving flow in the microcirculation. METHODS: We conducted a retrospective analysis of patients with subcortical stroke who experienced deterioration and were treated with eptifibatide (loading dose 180 microg/kg; infusion 2 m microg/kg/min) for 24-48 h. Oral antiplatelet agents were started 6 h before discontinuation of eptifibatide. RESULTS: Twenty-four patients with subcortical strokes were treated. The median admission NIHSS score was 5.0, which worsened to 8.5 (motor 5.0) before starting eptifibatide. The median NIHSS score 24 h after starting eptifibatide was 5.5. At 24 h, 42% had motor NIHSS scores less than or equal to pre-deterioration scores (50% for total NIHSS), and 50% had improved at least 1 motor point compared to pre-eptifibatide scores, which was sustained until hospital discharge. At discharge, the median total NIHSS score was 4.5. Ninety-two percent of patients were discharged home or to inpatient rehabilitation. Treatment was stopped early in 1 case due to a platelet drop <100,000/microl. No systemic or intracerebral bleeding occurred. CONCLUSIONS: Eptifibatide infusion may be safe in patients with subcortical ischemic strokes. Future studies are needed to test the safety and potential efficacy of this agent in subcortical stroke progression. Copyright (c) 2009 S. Karger AG, Basel.
BACKGROUND: There is no proven treatment for stroke progression in patients with subcortical infarcts. Eptifibatide, a glycoprotein IIb/IIIa inhibitor, might halt stroke progression by improving flow in the microcirculation. METHODS: We conducted a retrospective analysis of patients with subcortical stroke who experienced deterioration and were treated with eptifibatide (loading dose 180 microg/kg; infusion 2 m microg/kg/min) for 24-48 h. Oral antiplatelet agents were started 6 h before discontinuation of eptifibatide. RESULTS: Twenty-four patients with subcortical strokes were treated. The median admission NIHSS score was 5.0, which worsened to 8.5 (motor 5.0) before starting eptifibatide. The median NIHSS score 24 h after starting eptifibatide was 5.5. At 24 h, 42% had motor NIHSS scores less than or equal to pre-deterioration scores (50% for total NIHSS), and 50% had improved at least 1 motor point compared to pre-eptifibatide scores, which was sustained until hospital discharge. At discharge, the median total NIHSS score was 4.5. Ninety-two percent of patients were discharged home or to inpatient rehabilitation. Treatment was stopped early in 1 case due to a platelet drop <100,000/microl. No systemic or intracerebral bleeding occurred. CONCLUSIONS:Eptifibatide infusion may be safe in patients with subcortical ischemic strokes. Future studies are needed to test the safety and potential efficacy of this agent in subcortical stroke progression. Copyright (c) 2009 S. Karger AG, Basel.
Authors: J P Mohr; L R Caplan; J W Melski; R J Goldstein; G W Duncan; J P Kistler; M S Pessin; H L Bleich Journal: Neurology Date: 1978-08 Impact factor: 9.910
Authors: Pitchaiah Mandava; William Dalmeida; Jane A Anderson; Perumal Thiagarajan; Roderic H Fabian; Raymond U Weir; Thomas A Kent Journal: Transl Stroke Res Date: 2010-09 Impact factor: 6.829
Authors: Farhaan S Vahidy; William J Hicks; Indrani Acosta; Hen Hallevi; Hui Peng; Renganayaki Pandurengan; Nicole R Gonzales; Andrew D Barreto; Sheryl Martin-Schild; Tzu-Ching Wu; Mohammad H Rahbar; Arvind B Bambhroliya; James C Grotta; Sean I Savitz Journal: Neurology Date: 2014-06-25 Impact factor: 9.910